share_log

Chardan Capital Reiterates Buy on SAB Biotherapeutics, Maintains $3 Price Target

Chardan Capital Reiterates Buy on SAB Biotherapeutics, Maintains $3 Price Target

Chardan Capital重申買入SAB Biotherapeutics,維持3美元的目標股價
Benzinga ·  2023/06/15 04:13

Chardan Capital analyst Keay Nakae reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $3 price target.

Chardan Capital分析師Keay Nakae重申SAB Biotherapeutics(納斯達克股票代碼:SABS)爲買入,並維持3美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論